Programme Thesis
Quest for Health (operated by SEMIA, Strasbourg) is France's largest health incubator, purpose-built to shepherd early-stage biotech, medtech, and digital health ventures from idea to Series A through a stacked instrument pathway. It exists as a public-private hybrid to anchor health innovation in the Grand Est region and funnel promising projects into EU-level funding (i-Lab, EIC Accelerator). Its new Biotech-Pharma track explicitly targets computational and AI-driven drug discovery ventures, reflecting a strategic pivot toward asset-light, platform-model biotech.
Selection Criteria
• Scientific innovation & differentiation: novel approach with at least proof-of-concept data; literature or benchmark comparison expected
• Market size & unmet need: large addressable market (oncology, AMR, antiviral resistance qualify strongly)
• Commercialisation pathway: clear route to first paying customer or pilot within 12–18 months post-incubation
• Team capability: relevant scientific/technical expertise; solo founders accepted at pre-seed but advisory board expected
• Instrument fit: Bourse Grand Est requires Grand Est regional anchor or credible relocation commitment; WiClub Santé requires pitch to industrial club members (pharma/medtech corporates); EIC readiness assessed at TRL 4–6
• Regional economic impact: job creation potential in Grand Est; partnerships with local research institutions (IGBMC, Inserm Strasbourg, University of Strasbourg) valued
• IP posture: freedom-to-operate or patent strategy expected for later instruments (not blocking at Bourse stage)
• Sector alignment: health, biotech, medtech, digital health; AI applied to drug discovery explicitly welcomed under Biotech-Pharma track
Past Winners / Cohort Profiles
SEMIA's Quest for Health portfolio skews toward medtech devices and therapeutic biotech (biologics, small-molecule optimisation), with a growing digital/AI health cohort from ~2022 onward. Named portfolio examples include Carbios (bioplastics via enzymology, spun out via SEMIA pathway), InVivo Therapeutics adjacents, and multiple diagnostics/imaging startups. More recently the incubator has backed AI-driven clinical decision tools and in-silico drug screening platforms. The Biotech-Pharma track (launched 2024–2025) is explicitly aimed at computational biology and AI/pharma ventures — so this track is relatively new and the archetype winner is still being defined, which is an advantage for a differentiated early mover. WiClub Santé winners typically have at least one named pharma or medtech pilot customer identified at pitch stage.
Ideal Candidate Fingerprint
The platonic ideal applicant is a scientist-founder with a PhD or equivalent technical depth, a validated proof-of-concept on a published benchmark, and at least one named pharma or hospital partner willing to run a pilot. They are targeting a large indication (oncology, rare diseases, AMR) with a platform approach that can expand across multiple targets, and are either based in Grand Est or willing to register a legal entity there. For the Biotech-Pharma track specifically, an AI/computational tool that integrates with existing pharma workflows (no wet lab required to generate revenue) is increasingly the archetype.
Recommended Framing
Eniola should lead with the Servier connection as a named pilot partner — Servier is headquartered in Suresnes (Paris) but is a major WiClub Santé-type industrial partner, and having a letter of intent or even informal interest from Servier transforms this from 'promising algorithm' to 'revenue-ready platform with a named first customer.' The 100% mutation coverage vs 17.6% for structure-limited competitors is the single most compelling slide: WiClub Santé industrial reviewers (pharma BD teams) will immediately recognise that crystallography bottleneck as a real operational pain point. Frame the Grand Est angle by pointing to Paris-Saclay / I2BC and Institut Pasteur as scientific validators, and signal willingness to establish a legal entity in Grand Est if that unlocks Bourse funding — the Strasbourg–Paris corridor is well-trodden for biotech ventures.
Watch Out
• Geography mismatch: Bourse Grand Est (€30K) requires a Grand Est regional anchor; if Eniola incorporates in Île-de-France without a Grand Est address, this instrument is blocked — confirm with Romain Neidl at the 29 Jun meeting whether a co-location (e.g., SEMIA's own incubation space in Strasbourg) would satisfy this requirement
• Solo founder risk: WiClub Santé and EIC reviewers routinely flag single-person teams; an SAB (Scientific Advisory Board) member from I2BC, Pasteur, or Sanofi should be formalised before the WiClub pitch
• AUROC 0.634 headline: pharma-literate reviewers may compare this unfavourably to mCSM-lig (0.70) without reading the coverage argument — prepare a one-slide reframe showing coverage × accuracy as the correct product metric, not AUROC alone
• Pre-incorporation status: most instruments beyond the Bourse require a legal entity (SAS/SASU); Eniola should incorporate before or immediately after the incubator intake meeting
• No IP filed: freedom-to-operate and provisional patent will be asked about by WiClub Santé industrial members — ESM-2 is Meta/academic, ECFP4 is open, so the protectable layer is the trained model weights and the delta-embedding method; a prior-art search and provisional filing strategy should be articulated